These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 31678602)

  • 21. Cost-Effectiveness Analysis of Hepatitis B Virus Screening and Management in Patients With Hematologic or Solid Malignancies Anticipating Immunosuppressive Cancer Therapy.
    Hwang JP; Huang D; Vierling JM; Suarez-Almazor ME; Shih YT; Chavez-MacGregor M; Duan Z; Giordano SH; Hershman DL; Fisch MJ; Cantor SB
    JCO Clin Cancer Inform; 2019 Mar; 3():1-12. PubMed ID: 30892921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Screening for and management of hepatitis B virus reactivation in patients treated with anti-B-cell therapy.
    Kusumoto S; Tobinai K
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):576-83. PubMed ID: 25696914
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma.
    Matsue K; Kimura S; Takanashi Y; Iwama K; Fujiwara H; Yamakura M; Takeuchi M
    Cancer; 2010 Oct; 116(20):4769-76. PubMed ID: 20597091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of hepatitis B reactivation in hepatitis B surface antigen seronegative and core antibody seropositive kidney transplant recipients.
    Querido S; Weigert A; Adragão T; Rodrigues L; Jorge C; Bruges M; Machado D
    Transpl Infect Dis; 2019 Feb; 21(1):e13009. PubMed ID: 30295412
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies.
    Lalazar G; Rund D; Shouval D
    Br J Haematol; 2007 Mar; 136(5):699-712. PubMed ID: 17338776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy.
    Yamauchi N; Maruyama D; Choi I; Atsuta Y; Sakai R; Miyashita K; Moriuchi Y; Tsujimura H; Kubota N; Yamamoto G; Igarashi T; Izutsu K; Yoshida S; Kojima K; Uchida T; Inoue Y; Tsukamoto N; Ohtsuka E; Suzuki S; Inaguma Y; Ichikawa S; Gomyo H; Ushijima Y; Nosaka K; Kurata M; Tanaka Y; Ueda R; Mizokami M; Kusumoto S
    Cancer Sci; 2021 May; 112(5):1943-1954. PubMed ID: 33576088
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy.
    Niitsu N; Hagiwara Y; Tanae K; Kohri M; Takahashi N
    J Clin Oncol; 2010 Dec; 28(34):5097-100. PubMed ID: 20837949
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overuse of prophylaxis in HBsAg and/or anti-HBc positive patients after increasing awareness to prevent reactivation in patients receiving immunosuppressive therapies: How rational are our prophylaxis decisions according to the literature?
    Yenilmez E; Cetinkaya RA
    Infez Med; 2019 Sep; 27(3):299-307. PubMed ID: 31545774
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of preventing hepatitis B virus reactivation in patients with lymphoma and resolved HBV infection.
    Tsou HH; Yang HC; Hsiao CF; Hsiung CA; Liu TW; Chuang MH; Wu HY; Hsu YT; Tsui CW; Chen PJ; Cheng AL; Hsu C;
    J Formos Med Assoc; 2020 Jan; 119(1 Pt 2):335-344. PubMed ID: 31235201
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
    Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
    Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer.
    Borentain P; Colson P; Coso D; Bories E; Charbonnier A; Stoppa AM; Auran T; Loundou A; Motte A; Ressiot E; Norguet E; Chabannon C; Bouabdallah R; Tamalet C; Gérolami R
    J Viral Hepat; 2010 Nov; 17(11):807-15. PubMed ID: 20002298
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors?
    Busch MP
    Transfus Clin Biol; 2004 Feb; 11(1):26-32. PubMed ID: 14980546
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition.
    Zhang X; Zhou Y; Chen C; Fang W; Cai X; Zhang X; Zhao M; Zhang B; Jiang W; Lin Z; Ma Y; Yang Y; Huang Y; Zhao H; Xu R; Hong S; Zhang L
    J Immunother Cancer; 2019 Nov; 7(1):322. PubMed ID: 31753012
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with Lamivudine.
    Simpson ND; Simpson PW; Ahmed AM; Nguyen MH; Garcia G; Keeffe EB; Ahmed A
    J Clin Gastroenterol; 2003 Jul; 37(1):68-71. PubMed ID: 12811213
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The difficulties of managing severe hepatitis B virus reactivation.
    Roche B; Samuel D
    Liver Int; 2011 Jan; 31 Suppl 1():104-10. PubMed ID: 21205146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness analysis of hepatitis B vaccine booster in children born to HBsAg-positive mothers in rural China.
    Wang Y; Shi JF; Wang L; Yan Y; Yao H; Dai M; Chen T; Qu C
    Int J Infect Dis; 2019 Jan; 78():130-139. PubMed ID: 30466898
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reactivation of hepatitis B virus in cancer patients treated with chemotherapy for solid tumors. Is the prophylaxis really required?
    Federico A; Brancaccio G; Dallio M; Iodice P; Fabozzi A; Del Prete S; Ciardiello F; Loguercio C; Gaeta GB
    Dig Liver Dis; 2017 Feb; 49(2):197-201. PubMed ID: 27899262
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival.
    Chen KL; Chen J; Rao HL; Guo Y; Huang HQ; Zhang L; Shao JY; Lin TY; Jiang WQ; Zou DH; Hu LY; Wirian ML; Cai QQ
    Chin J Cancer; 2015 May; 34(5):225-34. PubMed ID: 26058465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost Effectiveness of Universal Hepatitis B Virus Screening in Patients Beginning Chemotherapy for Sarcomas or GI Stromal Tumors.
    Tan G; Zhou K; Tan CH; Matchar DB; Farid M; Quek R; Ngeow J
    J Glob Oncol; 2016 Aug; 2(4):186-199. PubMed ID: 28717701
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical characteristics and molecular analysis of hepatitis B virus reactivation in hepatitis B surface antigen-negative patients during or after immunosuppressive or cytotoxic chemotherapy.
    Hayashi K; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Tachi Y; Ishikawa T; Katano Y; Yoshioka K; Toyoda H; Kumada T; Goto H; Hirooka Y
    J Gastroenterol; 2016 Nov; 51(11):1081-1089. PubMed ID: 26943169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.